January Therapeutics, an emerging oncology research and development company, announces a panel of renown scientific advisors
January Therapeutics, Inc., was formed around a proprietary therapeutic platform dubbed the Chemistry-enabled Albumin Nanoparticle (CAN) Platform. The company recently named a number of experts to provide advice on the development of the various compounds in the January pipeline.
"We have assembled a distinctive group of respected leaders in the fields of cancer research and drug development," said Neil Raheja, Ph.D., January's CEO & CSO, "and we look forward to collaborating with them in the development of our promising pipeline of therapeutics."
The scientific advisors include:
Copyright © 2020 January Therapeutics - All Rights Reserved.